Akari Therapeutics, Plc (AKTX)
Oxford Ledge is still expanding full research coverage of AKTX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Akari develops cancer-fighting antibody-drug conjugates using a novel RNA-splicing payload paired with different tumor-targeting antibodies.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Shareholder vote results; Financial statements and exhibits 2026-07-02
- 8-K Entry into material agreement; Financial statements and exhibits 2026-06-26
- S-1/A Amended registration statement 2026-06-26
- DEF 14A Proxy statement for shareholder vote 2026-06-04
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-05-22
Source: SEC EDGAR.
Annual results
5 years of annual figures for AKTX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$17.3M | $0.00 |
| 2024 | — | -$19.8M | $0.00 |
| 2023 | — | -$10.0M | $0.00 |
| 2022 | — | -$17.7M | $0.00 |
| 2021 | — | -$17.4M | $0.00 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for AKTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AKTX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.